Epidemiological burden of female genital tract cancers in the United States, 1999–2024
Authors: Yazeed Albalawi , Khaled Khormi , Eynar Abdulmoaatni Almazroy , Ali Alodayli , Haneen Alkhamisi , Lauy Alzahrani , Norah Alkahtani , Manar Alqahtani , Amjad Alaqil , Batool Alsubait , Nadiyah Salem Althunayan
Abstract
Background: Female genital tract cancers (FGTCs) remain a leading contributor to women’s cancer mortality in the United States. This study provides the first comprehensive, population level assessment of temporal, demographic, and geographic patterns in FGTC mortality from 1999 through 2024.
Methodology: We extracted death certificate data from the CDC WONDER database (ICD10 C51–C58) and calculated crude and age adjusted mortality rates (AAMRs) per 100,000 women using the 2000 U.S. standard population. Trends were examined with Joinpoint regression to estimate annual percent change (APC). Analyses were stratified by age, race/ethnicity, census region, state, and NCHS urban–rural classification
Results: From 1999–2024, 850,404 deaths attributed to FGTCs were recorded. The overall AAMR was 10.6 per 100,000. Mortality declined from 1999 to 2018 (APC: –1.35, p = 0.0396), but a marked increase occurred between 2018 and 2021 (AAMR rising from 8.8 to 16.8 per 100,000), followed by stabilization through 2024. Pronounced disparities were observed: non Hispanic Black women experienced the highest average AAMR (21.6), followed by non Hispanic White (17.1) and American Indian/Alaska Native women (14.0). Regional and urban rural heterogeneity was evident with the Northeast and Midwest showing higher AAMRs and nonmetropolitan areas demonstrating persistently elevated rates; state level burdens peaked in the District of Columbia and several Appalachian states. The COVID19 pandemic coincided with the 2018–2021 mortality surge, likely reflecting diagnostic and treatment disruptions in addition to direct pandemic mortality.
Conclusion: Although FGTC mortality fell through 2018—coinciding with advances in screening, surgical deescalation, and targeted therapies—progress stalled and partially reversed around the pandemic period. Persistent racial, geographic, and rural–urban inequities underscore the need for equity focused interventions: reinforce screening and vaccination programs, expand access to specialty oncology care (including teleoncology and regional referral pathways), and prioritize policies that mitigate social determinants driving excess mortality.
Keywords: Epidemiology, female genital tract cancers, CDC WONDER, United States.
Pubmed Style
Yazeed Albalawi, Khaled Khormi, Eynar Abdulmoaatni Almazroy, Ali Alodayli, Haneen Alkhamisi, Lauy Alzahrani, Norah Alkahtani, Manar Alqahtani, Amjad Alaqil, Batool Alsubait, Nadiyah Salem Althunayan. Epidemiological burden of female genital tract cancers in the United States, 1999–2024. AMEM. 2026; 08 (November 2026): -. doi:10.24911/amem.15-3236
Publication History
Received: October 13, 2026
Revised: October 15, 2026
Accepted: October 19, 2026
Published: November 08, 2026
Authors
Yazeed Albalawi
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.
Khaled Khormi
Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Eynar Abdulmoaatni Almazroy
King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Ali Alodayli
Hail Health Cluster, Hail, Saudi Arabia.
Haneen Alkhamisi
King Abdulaziz University, Jeddah, Saudi Arabia.
Lauy Alzahrani
Shaqra University, Shaqra, Saudi Arabia.
Norah Alkahtani
King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Manar Alqahtani
King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Amjad Alaqil
King Faisal University, Al-Ahsa, Saudi Arabia.
Batool Alsubait
Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Nadiyah Salem Althunayan
Faculty of Medicine, Alexandria University, Alexandria, Egypt.